
Sydnexis: Innovating proprietary treatments for pediatric progressive myopia.
Sydnexis, a pioneering company in pediatric ophthalmology, focuses on developing innovative treatments for progressive myopia in children. The company's core mission is to decrease the progression of myopia through a novel, stable, and comfortable topical eyedrop that is administered once daily at bedtime. Sydnexis aims to improve the quality of life for children affected by myopia by providing an effective and easy-to-use treatment option. Their market focus is primarily on pediatric patients who are experiencing progressive myopia.
Key figures affiliated with Sydnexis include leading experts in pediatric ophthalmology and experienced pharmaceutical developers. The company has conducted significant research, including the STAR Study, to validate the efficacy of their treatment. Sydnexis's notable achievements include the development of a proprietary eyedrop formulation that has shown promising results in clinical trials. The overall impact of Sydnexis lies in its potential to revolutionize the treatment of pediatric myopia, offering hope to millions of children worldwide who suffer from this condition.

Visus Therapeutics
visustx.com

Nexis Vision

OcuTerra Therapeutics
ocuterratx.com

Treehouse Eyes
treehouseeyes.com

Surface Ophthalmics

Visiox
visioxpharma.com

Hyperion DeFi
eyenovia.com

EyeCyte
eyecyte.com

Ocular Science
ocularscience.com

Scynexis
scynexis.com

TherOptix

Myra Vision
myravision.com

Ocular Therapeutix
ocutx.com

MediPrint Ophthalmics

Synergeyes
synergeyes.com
Companies similar to Sydnexis include Visus Therapeutics, Nexis Vision, OcuTerra Therapeutics and Treehouse Eyes.
Sydnexis was founded in 2014.
Sydnexis' headquarters is located in Del Mar, CA, US.
Sydnexis' most recent funding round was for $45M (USD) in August 2021.
As of Aug 10, 2021, Sydnexis has raised a total of $50.5M (USD).
Sydnexis has 33 employees as of Feb 5, 2024.